- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Ferring announces data from its Phase III ESTHER trials
4 July 2016 • Author: Victoria White, Digital Content Producer
Ferring Pharmaceuticals have announced data from their ESTHER trials at the Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE).
ESTHER-1, a randomised, assessor-blind, controlled, multicentre Phase III trial in women aged 18–40 years undergoing their first cycle of in-vitro fertilisation (IVF) or intracytoplasmic injection (ICSI), assessed an individualised dosing regimen of follitropin delta compared to follitropin alfa (conventional dosing regimen).
The individualised dosing regimen for follitropin delta was based on the patient’s serum anti-Müllerian hormone (AMH) level (a parameter used to assess ovarian reserve) and body weight. This individualised dosing regimen was used from the first day of controlled ovarian stimulation to determine an appropriate dose of FSH with the aim of minimising the risk of poor and excessive ovarian response in IVF or ICSI.
Non-inferiority was demonstrated for the co-primary endpoints of ongoing pregnancy rate (30.7% vs 31.6%) and ongoing implantation rate (35.2% vs 35.8%) for follitropin delta compared to follitropin alfa.
Translating personalised medicine into reproductive health
Secondary endpoints, including the number of oocytes retrieved and number of blastocysts obtained, were comparable between both groups. In addition, ovarian hyperstimulation syndrome (OHSS) and/or OHSS preventive interventions occurred less frequently in women receiving follitropin delta than in women in the follitropin alfa group.
“This trial is an integral part of Ferring’s commitment to help couples conceive by translating the practice of personalised medicine into reproductive health and fertility,” commented Joan-Carles Arce, M.D., Ph.D., Vice President Clinical Research & Development, Ferring. “We believe that by focusing on innovative and personalised approaches to treatment, we can continue to lead the way in assisted reproductive technology.”
Additional data from the ESTHER-2 trial presented at the meeting demonstrated no increased immunogenicity risk following controlled ovarian stimulation with follitropin delta after exposure in repeated cycles.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics